Oppenheimer analyst Owen Lau downgrades Focus Finl Partners (NASDAQ:FOCS) from Outperform to Perform.
Integra LifeSciences Expects FY23 Revenues Of $1.60B-$1.62B Vs. Consensus Of $1.62B, Adjusted EPS Of $3.43-$3.51 Vs. $3.52 Estimate
The guidance reflects a sequential improvement from first to second-half growth primarily driven by the gradual recovery of supply throughout the year, 2022 normalization from private label business, the recovery of
